232 completed, 54 terminated, 48 unknown, 38 active not recruiting. 431 Phase 3, 62 Phase 2.
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes Each treatment cycle is 28-days. Azacitidine 75 mg/m² is administered subcutaneously or intravenously on Days 1-7 of each cycle. Sonrotoclax is orally administered once daily on Days 1-14 within each - MDS (Myelodysplastic Syndrome) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 10 | 2028-09-01 | 2026-11-12 |
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) Roxadustat, Placebo - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Kyntra Bio | 201 | 2027-04-01 | 2026-07-23 |
| A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients. FXS6837 Capsule - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 20 | 2027-01-26 | 2026-11-04 |
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. FXS6837 Capsule, Eculizumab infusion - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 90 | 2026-12-10 | 2026-08-05 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera AG-236, Placebo - Polycythemia Vera | Phase 2 / Phase 3 | Not yet recruiting | Agios Pharmaceuticals, Inc. | 245 | 2026-11-01 | 2026-10-13 |
| Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes Luspatercept - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 75 | 2026-10-31 | 2026-10-26 |
| A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy VSA012, Eculizumab (Soliris®) - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Not yet recruiting | Bisirna Therapeutics (Suzhou) Co., Ltd. | 70 | 2026-10-29 | 2026-09-11 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-29 | 2026-11-05 |
| Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients N-acetylcysteine - Aplastic Anemia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 142 | 2026-09-30 | 2026-09-16 |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-11-06 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-11-05 |
| A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment Avatrombopag 20 mg Oral Tablet - Aplastic Anemia | Phase 2 / Phase 3 | Not yet recruiting | Swedish Orphan Biovitrum | 26 | 2026-07-31 | 2026-08-26 |
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF) - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | Ruijin Hospital | 168 | 2026-07-30 | 2026-07-29 |
| A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 35 | 2026-06-11 | 2026-08-05 |
| A Long-term Efficacy and Safety of NTQ5082 Capsules NTQ5082 capsules 200 mg - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 78 | 2026-06-01 | 2025-09-17 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-11-10 |
| INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) Sapablursen, Placebo - Polycythemia Vera | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 250 | 2026-05-25 | 2026-10-29 |
Showing 20 of 431. Sign in to see all of them.
Myelodysplastic Syndromes (151) · Leukemia, Myeloid, Acute (106) · Leukemia (92) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (85) · Myeloproliferative Disorders (65) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (64) · Leukemia, Myeloid, Chronic-Phase (58) · Primary Myelofibrosis (58) · Hemoglobinuria, Paroxysmal (50) · Leukemia, Myelomonocytic, Chronic (45) · Lymphoma (36) · Polycythemia Vera (35) · Lymphoma, Non-Hodgkin (34) · Anemia (32) · Leukemia, Myeloid, Accelerated Phase (32)
Hemic and Lymphatic Diseases (431) · Hematologic Diseases (414) · Neoplasms (240) · Neoplasms by Histologic Type (226) · Leukemia, Myeloid (204) · Pathological Conditions, Signs and Symptoms (176) · Myeloproliferative Disorders (168) · Pathologic Processes (168) · Disease Attributes (159) · Chronic Disease (153) · Leukemia (135) · Anemia (105) · Immune System Diseases (89) · Immunoproliferative Disorders (80)
Cytarabine (41) · Cyclophosphamide (40) · Imatinib Mesylate (34) · Busulfan (32) · nilotinib (26) · Etoposide (24) · eculizumab (24) · ruxolitinib (23) · Methotrexate (22) · Azacitidine (21) · Daunorubicin (21) · fludarabine phosphate (21) · Hydroxyurea (20) · Peripheral Blood Stem Cell Transplantation (20) · Filgrastim (18)
Novartis Pharmaceuticals (37) · Alexion Pharmaceuticals, Inc. (12) · European Organisation for Research and Treatment of Cancer - EORTC (12) · Celgene (11) · Bristol-Myers Squibb (8) · Fred Hutchinson Cancer Center (8) · M.D. Anderson Cancer Center (8) · AOP Orphan Pharmaceuticals AG (7) · Merck Sharp & Dohme LLC (7) · Alliance for Clinical Trials in Oncology (6) · Children's Oncology Group (6) · Incyte Corporation (6) · Medical College of Wisconsin (6) · National Cancer Institute (NCI) (6) · Amgen (5)
United States (209) · France (135) · Germany (134) · Italy (130) · United Kingdom (118) · Spain (109) · Canada (105) · Belgium (86) · Australia (80) · Poland (78) · Czechia (75) · Netherlands (75) · South Korea (72) · China (68) · Hungary (65)
Mary Horowitz, MD (5) · Qifa Liu (4) · Alan K. Burnett, MD, FRCP (3) · Heinz Gisslinger, MD (3) · Ruediger Hehlmann, MD (3)
PMID 31375516, PMID 36184192, PMID 37042865, PMID 39516087, PMID 39535306, PMID 40535755, PMID 40694294, PMID 41958363, PMID 42316774, PMID 23515925, PMID 23620574, PMID 23911705, PMID 24859364, PMID 26069290, PMID 28273028, PMID 28962635, PMID 29396713, PMID 29926156, PMID 30523055, PMID 32499241, PMID 33275766, PMID 33811823, PMID 34526067, PMID 35235189, PMID 36815378, PMID 37267439, PMID 37311468, PMID 37341189, PMID 37553873, PMID 38065202, PMID 38295280, PMID 38477987, PMID 38727860, PMID 39079163, PMID 40447351, PMID 40720060, PMID 40978458, PMID 41890273, PMID 42085603, PMID 42452788, PMID 12637609, PMID 15010373, PMID 15459300, PMID 15761020, PMID 16136166, PMID 16333838, PMID 16484584, PMID 16932345, PMID 16960978, PMID 16990386
2023 (17), U01HL069294 (6), 2009 (5), 2015 (5), 2018 (5), 2019 (5), U10CA021115 (5), 2014 (4), 2016 (4), 2017 (4), U24CA076518 (4), 2025 (3), U10CA031946 (3), 2004 (2), 2005 (2)